Walmart halts H-1B visa offers amid Trump’s $100,000 fee increase - Bloomberg
Investing.com - Canaccord Genuity raised its price target on Seres Therapeutics (NASDAQ:MCRB) to $22.00 from $14.00 on Wednesday, while maintaining a Buy rating on the stock. According to InvestingPro data, the stock currently trades at $17.56 with a market capitalization of $154 million, and analysts’ targets range from $6 to $22.
The research firm cited positive feedback regarding the higher probability of FDA approval for the company’s products as the primary reason for the significant price target increase.
Seres Therapeutics currently holds approximately $45.4 million in cash and expects to receive a payment of about $25 million from Nestle in the third quarter of 2025.
The company’s current financial position is expected to support its cash runway into the second quarter of 2026, according to Canaccord Genuity’s analysis.
The research firm expressed optimism about the use of Bloodstream Infections (BSIs) as a primary endpoint for Seres’ next study, anticipating a quick readout once the study begins, while also noting that results from the company’s strategic partnership search are still pending.
In other recent news, Seres Therapeutics reported a larger-than-expected loss for the second quarter of 2025, with earnings per share coming in at -$2.27, significantly missing the forecast of -$0.09. This earnings miss has brought attention to the company’s ongoing efforts in its development pipeline, especially the SER-155 program. The company has received constructive feedback from the FDA on its Phase 2 study protocol for SER-155, which is designed to prevent bloodstream infections in adults undergoing allogeneic hematopoietic stem cell transplants. SER-155 has also been granted Breakthrough Therapy designation by the FDA. Additionally, Seres Therapeutics recently sold its FDA-approved VOWST to Nestlé Health Science. The company is in the process of finalizing the SER-155 protocol and is actively seeking capital to advance the study. These developments reflect Seres Therapeutics’ focus on progressing its therapeutic initiatives despite recent financial challenges.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.